Artificially intelligent software has been developed to enhance medical treatments that use jets of electrified gas known as plasma. The computer code predicts the chemicals emitted by plasma devices, which can be used to treat cancer, promote healthy tissue growth and sterilize surfaces.
The plasma studied in the experiments is known as cold atmospheric plasma (CAP). When the CAP jet is turned on, numerous chemical species in the plasma take part in thousands of reactions. These chemicals modify the cells undergoing treatment in different ways, depending on the chemical composition of the jet. While scientists know that CAPs can be used to kill cancer cells, treat wounds and kill bacteria on food, it’s not fully understood why.
“This research is a step toward gaining a deeper understanding of how and why CAP jets work and could also one day be used to refine their use,” said Yevgeny Raitses, a managing principal research physicist at the U.S. Department of Energy’s Princeton Plasma Physics Laboratory (PPPL).
The project was completed by the Princeton Collaborative Low Temperature Plasma Research Facility (PCRF), a collaboration between researchers at PPPL and the George Washington University (GWU).
PPPL has a growing body of work that combines its 70 years of pioneering plasma research with its expertise in AI to solve societal problems. The Lab’s mission extends beyond using plasma to generate fusion power to its use in fields such as medicine and manufacturing, among others.
The software uses an approach known as a physics-informed neural network (PINN). In a PINN, data is organized into parts called nodes and neurons. The flow of the data mimics the way information is processed in the human brain. Laws of physics are also added to the code.
“Knowing what comes out of the jet is very important. Knowing what comes out accurately is very difficult,” said Sophia Gershman, a lead PPPL research engineer from the PCRF who worked on this collaborative project. The process would require several different devices to collect different kinds of information about the jet.
“In practical studies, it is difficult to go and utilize all of the various technologically advanced diagnostics all at once for each device and for various types of surfaces that we treat,” Gershman explained.
Calculating the chemical composition one nanosecond at a time
Li Lin, a research scientist from GWU and the paper’s primary author, said it’s also difficult to calculate the chemicals in a CAP jet because the interactions need to be considered a nanosecond at a time.
“When you consider that the device is in operation for several minutes, the number of calculations makes the problem more than simply computationally intensive. It’s practically impossible,” Lin said. “Machine learning allows you to bypass the complicated part.”
The project began with a small set of real-world data that was gathered using a technique known as Fourier-transform infrared absorption spectroscopy. The researchers used that small dataset to create a broader set of data. That data was then used to train the neural network using an evolutionary algorithm, which is a type of computer code inspired by nature that searches for the best answers using a survival-of-the-fittest approach.
Several successive batches of data are generated using slightly different approaches, and only the best datasets from each round are carried through to the next round of training until the desired results are achieved.
Ultimately, the team was able to accurately calculate the chemical concentrations, gas temperature, electron temperature and electron concentration of the cold atmospheric plasma jet based on data gathered during real-world experiments.
In a cold atmospheric plasma, the electrons—small, negatively charged particles—can be very hot, though the other particles are close to room temperature. The electrons can be at a low enough concentration that the plasma doesn’t feel hot or burn the skin while still being able to have a significant effect on the targeted cells.
On the path to personalized plasma treatment
Michael Keidar, the A. James Clark Professor of Engineering at GWU and a frequent collaborator with PPPL who also worked on this project, said the long-term goal is to be able to perform these calculations fast enough that the software can automatically adjust the plasma during a procedure to optimize treatment. Keidar is currently working on a prototype of such a “plasma adaptive” device in his lab.
“Ideally, it can be personalized. The way we envision it, you treat the patient, and the response of every patient will be different,” Keidar explained. “So, you can measure the response in real-time and then try to inform, using feedback and machine learning, the right settings in the plasma-producing device.”
More research needs to be done to perfect such a device. For example, this study looked at the CAP jet over time but at only one point in space. Further research would need to broaden the work so it considers multiple points along the jet’s output stream.
The study also looked at the plasma plume in isolation. Future experiments would need to integrate the surfaces treated by the plasma to see how that impacts the chemical composition at the treatment site.
More information: Li Lin et al, Data-driven prediction of the output composition of an atmospheric pressure plasma jet, Journal of Physics D: Applied Physics (2023). DOI: 10.1088/1361-6463/acfcc7
News
Scientists Discover a Hidden “Immune Organ” Inside the Skull
Researchers discovered lymph node-like immune hubs inside skull bone marrow that appear to act as rapid-response centers for the brain. For decades, the brain was thought to operate largely apart from the immune system. [...]
Engineered tRNAs and lipid nanoparticles target nonsense mutation cystic fibrosis
Researchers have developed a potential new approach for treating a form of cystic fibrosis caused by so-called nonsense mutations, combining chemically modified transfer RNAs with lipid nanoparticles designed to deliver the therapy directly to [...]
New pancreatic cancer drug carries a $39,800 monthly list price
A groundbreaking treatment for one of the most common forms of pancreatic cancer has been approved in pill form by the FDA. Revolution Medicines’ oral tablet daraxonrasib, branded as Rasonque, reduced the risk of [...]
Researchers Have Discovered a New Way To Reduce Chronic Nerve Pain
A cancer-linked protein called BRAF may help drive chronic nerve pain, and existing cancer drugs targeting it reduced pain sensitivity in preclinical models. Chronic nerve pain can persist long after an injury and often [...]
Our books now available worldwide!
Online Sellers other than Amazon, Routledge, and IOPP Indigo Global Health Care Equivalency in the Age of Nanotechnology, Nanomedicine and Artifcial Intelligence Global Health Care Equivalency In The Age Of Nanotechnology, Nanomedicine And Artificial [...]
Quantum-Enabled Regenerative Health: Reimagining Wellness, Precision Health and Longevity Medicine
Introduction Healthcare is approaching a frontier where the quantum portfolio could influence not only how disease is diagnosed and treated, but how health itself is measured, modeled, predicted and preserved. Quantum computing, quantum simulation, [...]
FDA Clears First-of-Its-Kind Nonmedication Treatment for PTSD
The FDA has cleared a system that uses brain activity data to personalize magnetic stimulation for PTSD, adding a new nonmedication treatment option. Every day in the United States, approximately 17.5 veterans die by suicide, [...]
FDA approves breakthrough drug to treat advanced pancreatic cancer
The Food and Drug Administration (FDA) approved on Wednesday a drug that could extend the survival of those with metastatic pancreatic cancer. The drug, called daraxonrasib, will be sold under the brand name Rasonque [...]
AI Decodes a Hidden DNA Signal Linked to Disease-Causing Mutations
Machine learning identifies the likely “initiator” and enables new predictions about DNA mutations that can cause disease. Every human cell depends on tens of thousands of genes being switched on at the right time [...]
Pope Leo Urges Global Response to Congo’s Deadliest Ebola Outbreak
Pope Leo called for international action to address the Ebola outbreak in the Democratic Republic of Congo. The epidemic has claimed over 2,500 lives and is the nation's largest recorded outbreak. The Pope emphasized [...]
Is there a summer COVID-19 surge this year? Yep, it’s ramping up again
Hantavirus. Ebola. West Nile. Measles. And, of course, cyclospora — that stomach parasite making people miserable across the country. Americans have plenty to worry about this summer. But remember COVID-19? It may not be [...]
Natural Compound in Broccoli Could Help Treat a Rare, Incurable Neurological Disease
Swinburne researchers have discovered how broccoli could help treat an extremely rare and incurable disease that affects only about 200 Australians. A naturally occurring compound in broccoli is being investigated as a possible treatment [...]
Antibody recycling, FcRn and the next generation of biologics
FcRn plays a central role in regulating the half-life of IgG antibodies and albumin, making it a critical target in both antibody engineering and autoimmune disease therapy. This article explores the biology of FcRn, [...]
Ebola kills 2,300 in three months with no vaccine available for Congo’s deadliest ever outbreak
It’s Congo’s 17th outbreak, with a toll that has eclipsed that of the country’s 2018-2020 outbreak when 2,299 deaths out of 3,481 cases were recorded. The latest data shows 101 new cases and 33 [...]
Beyond an Agency: How AI, Creativity and Commercialization Are Converging Into a New Growth Model
At a moment when AI is forcing a fundamental rethink of how work gets done, the life sciences industry is grappling with a deeper question: what role should human creativity play in an increasingly [...]
New $60 Blood Test Detects Lung Cancer Without Costly DNA Sequencing
A simple blood test that detects chemical changes in DNA identified more than 90% of stage 2-4 lung cancers in an early study, without relying on costly DNA sequencing. Researchers at Tel Aviv University and collaborating [...]















